The company’s new drug delivery instrument is slated to include an integrated electronic record-keeping feature, as well as improved needle placement compared to its dental injection device.
“There is a large and growing market for botulinum toxin (such as Botox and Dysport) injections globally, with over 8.4 million botulinum toxin injections annually in the U.S. alone. Recognizing this opportunity, we set out to develop a product concept and conducted a cosmetic injection instrument feasibility study to determine professional interest in a new cosmetic injection system,” chairman & interim CEO Leslie Bernhard said in prepared remarks.
Milestone conducted an extensive survey of over 150 medical professionals, including both plastic surgeons and cosmetic dermatologists. The physicians surveyed conduct regular botulinum toxin injections and are decision makers regarding the purchase of equipment and devices for their practice. Based on the results of the study, which indicated dissatisfaction with the current syringe-based technique, these medical professionals indicated a strong desire for improvement in the ability to inject precise dosage units and to minimize patient discomfort.
As a result, we proceeded with the development of a new cosmetic injection instrument that allows the clinician to inject accurate doses with the precision of a stylus pen that is designed for comfort and superior tactile feel. Each injection is verified with audible sound feedback confirming unit dose and each injection is documented with an electronic record.”
The company’s chief executive added that Milestone Scientific has finished the system’s design, manufactured a set of pre-production devices and completed a series of human factors studies. The company plans to start the instrument’s commercial launch in Europe, then moving to the U.S. and Asia.